Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The Swiss Federal Council rejected TARDOC outpatient tariff structure once again

On June 3, 2022, the Swiss Federal Council rejected TARDOC outpatient tariff structure version 1.3, which was submitted in December 2021. According to the Federal Council, major progress has been made, but version 1.3 does still not meet the legal requirements, in particular cost neutrality.

The Federal Council invited the tariff partners to continue developing the TARDOC outpatient tariff structure and insists that all relevant stakeholders take part in the process (including the association of health insurers santésuisse).

More information can be found on the website of the Federal Council. Opinions of the two health insurer companies, curafutura, and santésuisse, can be found here and here, respectively.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.